Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript

Harry Thomasian : And Brian, I’ll touch on your question around cash runway. I’ll start with the historical cash burn. So last year, 2023, our cash burn was about $68.5 million or an average of about $5.7 million per month. There’ll be some increased expenditures with the build-out of commercialization and manufacturing capabilities. But through financial management, we’re trying to reduce spend in other areas of the company. I will go back to my prepared remarks and reiterate that we’re continuing to evaluate various opportunities and we are confident in our ability to strengthen our balance sheet as we approach the planned launch of PRGN-2012.

Operator: [Operator Instructions]

Steven Harasym: I see no further questions. Lester, Let’s turn it back to Helen for concluding remarks.

Helen Sabzevari: Thank you, operator. And thank you to all of those that joined us for our update call today. As you can see, 2024 is poised to be a transformative year for us at Precigen, especially as we transition from a clinical to a commercial company. With pivotal Phase 2 data underway and the plans to submit a BLA in the second half of this year, we are poised to deliver health to patient population with no alternative and drive shareholder value. We look forward to communicating further in the coming weeks and months. Thank you again for joining us.

Operator: Ladies and gentlemen, this concludes today’s conference call. Thank you for joining. You may now disconnect.